Pacira BioSciences (FRA:82P) PE Ratio without NRI: 11.99 (As of Jul. 08, 2026) — 58% Below Median


FRA:82P Pacira BioSciences Inc FRA:82P
75 GF Score
Price €22.40
GF Value €25.72
! 8 Warning Signs
View Full Analysis

What is Pacira BioSciences PE Ratio without NRI?

Pacira BioSciences FRA:82P +2.75% 75 PE Ratio without NRI is 11.99 as of Jul. 08, 2026, which is 58% below its 10-year median of 28.22. GuruFocus rates FRA:82P with a GF Score™ of 75/100 and a GF Value™ of €25.72. The stock has 8 warning signs investors should review. Among 654 Drug Manufacturers companies, Pacira BioSciences ranks better than 79.36% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-08), Pacira BioSciences's share price is €22.40. Pacira BioSciences's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €1.87. Therefore, Pacira BioSciences's PE Ratio without NRI for today is 11.99.

During the past 13 years, Pacira BioSciences's highest PE Ratio without NRI was 310.62. The lowest was 5.35. And the median was 28.22.

Pacira BioSciences's EPS without NRI for the three months ended in Mar. 2026 was €0.52. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €1.87.

As of today (2026-07-08), Pacira BioSciences's share price is €22.40. Pacira BioSciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.10. Therefore, Pacira BioSciences's PE Ratio (TTM) for today is 219.61.

Warning Sign:

Pacira BioSciences Inc stock PE Ratio (=215.17) is close to 2-year high of 215.17.

During the past years, Pacira BioSciences's highest PE Ratio (TTM) was 1155.50. The lowest was 8.80. And the median was 68.97.

Pacira BioSciences's EPS (Diluted) for the three months ended in Mar. 2026 was €0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.10.

Pacira BioSciences's EPS (Basic) for the three months ended in Mar. 2026 was €0.06. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.10.


Pacira BioSciences  (FRA:82P) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Pacira BioSciences PE Ratio without NRI Related Terms


Pacira BioSciences PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences PE Ratio without NRI Chart

Pacira BioSciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.06 14.91 30.37 5.89 9.77

Pacira BioSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.90 15.83 12.20 9.77 10.42

FRA:82P vs ETON, AMPH, BIOA: PE Ratio without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's PE Ratio without NRI falls into.


FRA:82P
75GF Score
Pacira BioSciences Inc FRA:82P
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacira BioSciences PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Pacira BioSciences's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=22.40/1.868
=11.99

Pacira BioSciences's Share Price of today is €22.40.
Pacira BioSciences's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.87.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 11.99 mean?
Pacira BioSciences (FRA:82P) has a PE Ratio without NRI of 11.99 as of Jul. 08, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Pacira BioSciences and its competitors. This is 58% below median its historical median of 28.22. Over the past decade, Pacira BioSciences' PE Ratio without NRI has ranged from 5.35 to 310.62. According to the industry distribution chart, Pacira BioSciences ranks #135 out of 654 companies in the Drug Manufacturers industry, placing it in the top 20.6%.
Is Pacira BioSciences' PE Ratio without NRI too high?
Pacira BioSciences' current PE Ratio without NRI of 11.99 is 58% below median its 10-year median of 28.22. Over the past 10 years, this metric has ranged from a low of 5.35 to a high of 310.62. The Drug Manufacturers industry median PE Ratio without NRI is 20.75. Pacira BioSciences' value of 11.99 is 42.2% below this industry median. Based on the distribution chart, Pacira BioSciences ranks #135 out of 654 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pacira BioSciences has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' PE Ratio without NRI compare to ETON and AMPH?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #135 out of 654 companies for PE Ratio without NRI. This places Pacira BioSciences in the top 21% of its industry — outperforming the majority of peers. The industry median PE Ratio without NRI is 20.75. Pacira BioSciences' value of 11.99 is 42.2% below this benchmark. Historically, Pacira BioSciences' own PE Ratio without NRI has ranged from 5.35 to 310.62 over the past decade. While the company's 10-year median is 28.22 vs. the industry median of 20.75, Pacira BioSciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Drug Manufacturers company?
The median PE Ratio without NRI among Drug Manufacturers companies is 20.75, based on 654 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current PE Ratio without NRI of 11.99 is 42.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median PE Ratio without NRI is 20.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current PE Ratio without NRI is 11.99, which is 58% below median its own 10-year median of 28.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current PE Ratio without NRI of 11.99. The stock's GF Value™ is €25.72, compared to a current price of €22.40 — trading 12.9% below its estimated fair value. The current PE Ratio without NRI is 11.99, which is 58% below median its 10-year median of 28.22 and 42.2% below the Drug Manufacturers industry median of 20.75. Pacira BioSciences' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current PE Ratio without NRI is 11.99 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (FRA:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €22.40 is trading 12.9% below its estimated GF Value™ of €25.72.

Key valuation signals for FRA:82P:

  • PE Ratio without NRI: 11.99 (58% below median its 10-year median of 28.22)
  • GF Value™: €25.72 vs. price of €22.40 (12.9% below fair value)
  • GF Score™: 75/100 with 8 warning signs
  • Industry Position: 42.2% below the Drug Manufacturers median (#135 of 654)

No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacira BioSciences Business Description

Other Exchanges PCRX:USA82P:Germany
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
75GF Score

Get the complete analysis for FRA:82P

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.40
Price
€25.72
GF Value